Medservatory
USMLE Step 1Haematology and oncologyEP 10 of 14

Anticoagulants: target, monitoring test and reversal agent

Every anticoagulant in this lesson ends up blocking thrombin or factor Xa. Learn each drug's mechanism and the monitoring test and reversal agent follow from it.

  • 5:34 video
  • 3 min read
  • 19 sources
  • Published 15 Nov 2026
Video lesson · 5:34 · Watch on YouTubeSeries: Hematology: Anemia, Coagulation & Oncology Basics · @medservatory
Chapters (13)
By the end of this lesson

Explain the mechanism, monitoring test and reversal agent of unfractionated heparin, low molecular weight heparin, warfarin, the direct thrombin inhibitor dabigatran and the factor Xa inhibitors.

The short version

  1. Heparin works through antithrombin, is monitored with the aPTT and is reversed by protamine.
  2. Warfarin blocks vitamin K recycling, is monitored with the INR and is reversed by vitamin K plus factor replacement.
  3. Dabigatran, a direct thrombin inhibitor, is reversed by idarucizumab.
  4. Andexanet alfa is the textbook decoy for the factor Xa blockers, but it was withdrawn from the US market in 2025 and prothrombin complex concentrate is now preferred in the US.
  5. Match the antidote to the mechanism: a specific reversal agent for the wrong drug does nothing.

Where anticoagulants act: thrombin and factor Xa

Thrombin turns fibrinogen into fibrin, and factor Xa drives thrombin production. Every anticoagulant in this lesson ends up blocking thrombin or factor Xa: directly, through antithrombin, or by stopping the liver making the factors.[5][7]

Two tests do most of the monitoring: the aPTT for heparin, and the PT, reported as the INR, for warfarin.[1][2][5]

The anticoagulants at a glance
DrugMechanismMonitoringReversal
Unfractionated heparinBinds antithrombin; inhibits thrombin and factor XaaPTTProtamine
Low molecular weight heparinBinds antithrombin; mainly inhibits factor XaAnti-Xa level, when neededProtamine, much less effective
WarfarinBlocks vitamin K recycling; factors II, VII, IX, XINRVitamin K, plus PCC or FFP
DabigatranDirect thrombin inhibitorNo routine monitoringIdarucizumab
Rivaroxaban, apixabanDirect factor Xa inhibitorsNo routine monitoringAndexanet alfa (US withdrawn); PCC

Heparin: how it works through antithrombin

Unfractionated heparin does not block clotting factors itself. It binds antithrombin and changes its shape, making antithrombin about 1000 times better at inactivating thrombin and factor Xa.[1][5]

To block thrombin, heparin must grip thrombin and antithrombin together, so it needs a long chain, at least 18 sugar units. Low molecular weight heparin has short chains, so it mainly inhibits factor Xa.[1][14][15]

So the two heparins differ in what they hit. Unfractionated heparin grips thrombin and antithrombin together and inhibits both thrombin and factor Xa, whereas low molecular weight heparin mainly inhibits factor Xa.[1][5]

  • Unfractionated heparin is monitored with the aPTT, typically aiming for 60–80 seconds.[1][8][9]
  • Low molecular weight heparin, when monitoring is needed, is checked with an anti-Xa level.[1][5]
  • Heparin's special danger, apart from bleeding, is thrombocytopenia, the subject of the next lesson.[1][10]

Protamine: reversing heparin

Reversal is protamine, a positively charged protein that binds negatively charged heparin. It works much less well against low molecular weight heparin.[3][5]

Warfarin: vitamin K, the INR and reversal

Warfarin works in the liver. It blocks recycling of vitamin K, so factors II, VII, IX and X cannot be made properly.[2][5]

Factors already in the blood must decay first, so the effect is delayed: it builds over days rather than hours, and dose changes also take days to show.[2][5]

Protein C and protein S, the natural anticoagulants, also depend on vitamin K, and they fall first. Early on, warfarin can therefore be briefly procoagulant.[2][11]

  • Monitoring: the INR, with a target of 2–3 for atrial fibrillation and venous clots.[2][12][13]
  • Reversal: vitamin K. For urgent bleeding, prothrombin complex concentrate (PCC) supplies the factors immediately; fresh frozen plasma (FFP) is used if PCC is not available.[2][5][6]
  • Warfarin is teratogenic, so it is avoided in pregnancy.[2]

Direct oral anticoagulants (DOACs) and their reversal agents

The direct oral anticoagulants need no antithrombin. Dabigatran blocks thrombin directly. Rivaroxaban and apixaban block factor Xa directly. They are given at fixed doses without routine monitoring.[5][6]

Idarucizumab, an antibody fragment that binds dabigatran, is the reversal agent for the thrombin blocker.[4][6][18]

Andexanet alfa, a decoy factor Xa, was the specific antidote for the factor Xa blockers. It was withdrawn from the US market in 2025 after the FDA concluded that its clot risk outweighed its benefit, so prothrombin complex concentrate is now the usual choice.[5][18][19]

Two quick readings: INR and aPTT

Warfarin and an INR of 1.6
  1. Man with atrial fibrillation on warfarin: INR 1.6
  2. Target for atrial fibrillation: 2–3
  3. 1.6 is below 2–3, so he is under-anticoagulated and his stroke risk is not adequately covered
Heparin drip and an aPTT of 110 seconds
  1. Woman on a heparin drip: aPTT 110 seconds
  2. Typical aim: 60–80 seconds
  3. 110 is above 60–80, so the infusion is held or cut back; if she bleeds, give protamine

Practice question

Original · USMLE style
Your turnQB-MS-S1-HEME-011-01

A 74-year-old man with atrial fibrillation takes dabigatran. He falls at home and is brought to the emergency department. A head CT scan shows an acute intracranial haemorrhage. His last dose of dabigatran was 3 hours ago.

Which of the following is the most appropriate agent to reverse his anticoagulation?
Pick one option. Your answers stay on this device.

Common questions

What are the reversal agents for each anticoagulant?

Heparin is reversed by protamine, warfarin by vitamin K plus prothrombin complex concentrate or fresh frozen plasma, and dabigatran by idarucizumab. For the factor Xa blockers, andexanet alfa is the textbook decoy, but in the US prothrombin complex concentrate is now preferred.

How is each anticoagulant monitored?

Unfractionated heparin is monitored with the aPTT and warfarin with the INR. Low molecular weight heparin is checked with an anti-Xa level when needed, and the DOACs are given at fixed doses without routine monitoring.

Why can warfarin be procoagulant at the start of treatment?

Protein C and protein S, the natural anticoagulants, also depend on vitamin K, and they fall first. Early on warfarin can therefore be briefly procoagulant.

Why does low molecular weight heparin mainly inhibit factor Xa?

Blocking thrombin needs a chain long enough, at least 18 sugar units, to grip thrombin and antithrombin together. Low molecular weight heparin has short chains, so it mainly inhibits factor Xa.

Why was andexanet alfa withdrawn?

It was withdrawn from the US market in 2025 after the FDA concluded that its clot risk outweighed its benefit. Prothrombin complex concentrate is now the usual choice for reversing the factor Xa blockers.

Transcript

Read the full narration, by chapter679 words

0:00Four bleeding patients, four blood thinners, four antidotes

Four patients are bleeding, each on a different blood thinner. One takes warfarin, one has a heparin drip, one takes a thrombin blocker by mouth, and one a factor Xa blocker. Each needs a different antidote, and the mechanism tells us which. Today: for each anticoagulant, know its target, its monitoring test and its reversal agent.

0:23Where thrombin and factor Xa sit, and the two monitoring tests

Thrombin turns fibrinogen into fibrin, and factor Xa drives thrombin production. Every drug today ends up blocking thrombin or factor Xa: directly, through antithrombin, or by stopping the liver making the factors. Two tests do the monitoring: the APTT for heparin, and the PT, reported as the INR, for warfarin.

0:47Heparin works through antithrombin

Unfractionated heparin does not block factors itself. It binds antithrombin and changes its shape, making antithrombin about 1000 times better at inactivating thrombin and factor Xa.

1:01Long chains vs short chains: UFH vs LMWH

To block thrombin, heparin must grip thrombin and antithrombin together, so it needs a long chain, at least 18 sugar units. Low molecular weight heparin has short chains, so it mainly inhibits factor Xa. Unfractionated heparin is monitored with the

1:17aPTT monitoring and protamine reversal

APTT, typically aiming for 60 to 80 seconds. Low molecular weight heparin, when needed, is checked with an anti-Xa level. Reversal is protamine, a positively charged protein that binds negatively charged heparin. It works much less well against low molecular weight heparin. Heparin's special danger, apart from bleeding, is thrombocytopenia: the next lesson.

1:46Warfarin and the vitamin K cycle

Warfarin works in the liver. It blocks recycling of vitamin K, so factors two, seven, nine and 10 cannot be made properly. Factors already in the blood must decay first, so the full effect takes up to 72 hours. Protein C and protein S, the natural anticoagulants, also depend on vitamin K, and they fall first, so early on warfarin can be briefly procoagulant. Warfarin is monitored with the INR.

2:15INR, warfarin reversal and pregnancy

The target is two to three for atrial fibrillation and venous clots. Reversal is vitamin K. For urgent bleeding, prothrombin complex concentrate supplies the factors immediately; fresh frozen plasma is used if it is not available. Warfarin is also teratogenic, so it is avoided in pregnancy.

2:40DOACs: dabigatran and the factor Xa blockers

The direct oral anticoagulants need no antithrombin. Dabigatran blocks thrombin directly. Rivaroxaban and apixaban block factor 10 A directly. They are given at fixed doses without routine monitoring.

2:56Reversing DOACs: idarucizumab and andexanet alfa

Reversal: idarucizumab, an antibody fragment that binds dabigatran, for the thrombin blocker. Andexanet alfa, a decoy factor Xa, was the specific antidote for the Xa blockers. It was withdrawn from the US market in 2025 over clot risk, so prothrombin complex concentrate is now the usual choice.

3:19Two quick monitoring readings

Two quick readings. A man with atrial fibrillation on warfarin has an INR of 1.6. That is below two to three, so he is under-anticoagulated, and his stroke risk is not covered. A woman on a heparin drip has an APTT of 110 seconds. That is above 60 to 80, so the infusion is held or cut back; if she bleeds, we give protamine.

3:46Your turn: practice question

Your turn. A 74-year-old man with atrial fibrillation takes dabigatran. He falls and a head CT shows an acute intracranial haemorrhage. His last dose was 3 hours ago. Which of the following is the most appropriate agent to reverse his anticoagulation? A, protamine sulfate. B, vitamin K. C, idarucizumab. D, andexanet alfa. E, fresh frozen plasma. Pause here and decide.

4:21The answer and why

A is out: protamine neutralises heparin, not dabigatran. B is out: vitamin K lets the liver make new factors, which helps warfarin, but dabigatran does not work through vitamin K. D is out: andexanet is a decoy for factor Xa, and dabigatran blocks thrombin. E is out: plasma supplies factors, but it does not neutralise the drug, which would keep blocking thrombin. So the answer is C. Idarucizumab binds dabigatran itself and is the specific antidote.

4:57High-yield recap

Three things to keep. One: heparin works through antithrombin, is monitored by the APTT and is reversed by protamine. Two: warfarin blocks vitamin K recycling, is monitored by the INR and is reversed by vitamin K plus factor replacement. Three: dabigatran has idarucizumab; for the factor Xa blockers, andexanet is the textbook decoy, and prothrombin complex concentrate is now preferred. Next, heparin-induced thrombocytopenia.

Sources

Numbers in the text, e.g. [1], point here
  1. LITFL. Heparin. litfl.com/heparin/
  2. LITFL. Warfarin. litfl.com/warfarin/
  3. LITFL. Protamine. litfl.com/protamine/
  4. LITFL. Idarucizumab. litfl.com/idarucizumab/
  5. Bekka and Liakoni 2025, Br J Clin Pharmacol, anticoagulants overview. europepmc.org/article/PMC/PMC11862798
  6. Res Pract Thromb Haemost 2018, DOACs. europepmc.org/article/PMC/PMC6055488
  7. World J Gastrointest Endosc 2020, anticoagulant review. europepmc.org/article/PMC/PMC7415229
  8. TH Open 2024, therapeutic-intensity UFH management (aPTT range). europepmc.org/article/PMC/PMC11486528
  9. Blood Res 2016, aPTT range. europepmc.org/article/PMC/PMC5054248
  10. Thromb J 2005, heparin-induced thrombocytopenia update. europepmc.org/article/PMC/PMC1262784
  11. J Stroke 2015, procoagulant effect of early warfarin. europepmc.org/article/PMC/PMC4460341
  12. J Am Heart Assoc 2017, warfarin INR in atrial fibrillation. europepmc.org/article/PMC/PMC5524023
  13. J Thromb Thrombolysis 2016, warfarin guidance (INR for VTE). europepmc.org/article/PMC/PMC4715850
  14. UFH-antithrombin-thrombin complex, 18 saccharide units. europepmc.org/article/PMC/PMC12943893
  15. UFH-antithrombin-thrombin complex, 18 saccharide units (second source). europepmc.org/article/PMC/PMC13088229
  16. UFH-antithrombin-thrombin complex, 18 saccharide units (third source). europepmc.org/article/PMC/PMC12059864
  17. Br J Clin Pharmacol 2026, trends and variation in the use of andexanet alfa for DOAC reversal in NHS trusts in England (NICE recommendation, May 2021). europepmc.org/article/PMC/PMC13206202
  18. J Clin Med 2026, idarucizumab as the specific dabigatran antidote. europepmc.org/article/PMC/PMC13073382
  19. AABB News, 23 Dec 2025, andexanet alfa withdrawal. aabb.org/news-resources/news/article/2025/12/23/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market

The practice question is original and its patient is synthetic. Every fact is checked against the sources above in independent accuracy reviews. Always follow your local guidelines and your own laboratory’s ranges.

Image credits. Illustrations: Servier Medical Art (smart.servier.com), CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), adapted (recoloured, outlined, labelled): capsule, coagulation, syringe, liver lobule, IgG Fab arm, blood bag (recoloured), blood-test tube, thrombus. Also used: NIAID NIH BioArt (public domain): fibrinogen; Health Icons (CC0): IV drip, liver, pregnant. Original diagrams: the enzyme schematics, factor decay chart (schematic), number lines and the question card. No AI-generated teaching images.

Corrections. None so far. Spotted an error? Email info@medservatory.com with the lesson code MS-S1-HEME-011.

For exam study only, not medical advice. Read the medical disclaimer.

In this series

Playlist on YouTube
← Previous · EP 09Von Willebrand disease vs haemophilia: the labs that separate them
  1. EP 01Microcytic anaemia: four causes, four iron fingerprints5:37
  2. EP 02Hepcidin: why iron falls in inflammation5:34
  3. EP 03B12 vs folate deficiency: MMA, homocysteine and the nerves5:23
  4. EP 04Intravascular vs extravascular haemolysis: site and labs5:27
  5. EP 05G6PD deficiency vs hereditary spherocytosis, by mechanism5:36
  6. EP 06Sickle cell disease pathophysiology: HbS to vaso-occlusion5:26
  7. EP 07Primary haemostasis: platelet adhesion, activation and aggregation5:53
  8. EP 08Coagulation cascade: PT vs aPTT, pathway by pathway5:21
  9. EP 09Von Willebrand disease vs haemophilia: the labs that separate them5:32
  10. EP 10Anticoagulants: target, monitoring test and reversal agent5:34
  11. EP 11Heparin-induced thrombocytopenia: why a low count clots5:29
  12. EP 12DIC vs TTP vs HUS: mechanism and the PT/PTT5:33
  13. EP 13AML vs ALL vs CML vs CLL: leukemia classification made simple5:44
  14. EP 14Oncogenes vs tumour suppressor genes: one hit or two5:17